Day 3: PCa game changer! The British ProtecT trial update was presented by Prof. Freddie Hamdy (GB): “Survival from clinically- localised prostate cancer (PCa) remains very high over a median of 15 years (96-97%), irrespective of treatment allocation. Men with metastases do not necessarily die from PCa and those who do, they have lethality features yet to be identifiable, and are not easily impacted by multimodality treatment approaches.” Prof. Hamdy concluded that current risk- stratification methods are unreliable and that new tools are needed. However, the indications for active monitoring or surveillance can be expanded safely to intermediate-risk disease. Treatment decisions need to balance “trade-offs” between the reduction of metastases, long-term hormones, and local progression with radical treatments against their short-, medium-, and long-term impacts on sexual, urinary, and bowel function. On QoL, Prof. Jenny Donovan (GB) told the plenary session’s audience that based on the newly- published patient-reported outcomes, “Men newly-diagnosed with localised PCa can now carefully assess the trade-offs between the benefits and harms of treatment options: in the short, medium, and long-term and using their own values and priorities to make prudent and well-informed treatment decisions.”
Challenges in urogenital infections In his presentation, oncologist Prof. Andrea Alimonti (CH) stated that intra-tumoural microbiome plays a role in the development of prostate cancer (PCa). “The microbial species that reside in the urinary tract might be initiators of chronic inflammation in the prostate, ultimately leading to PCa by causing the development of PIA (proliferative inflammatory atrophy). Several species of pro-inflammatory bacteria and/or known uropathogens are enriched in men with PCa. The prostate tumour microbiota is different from the one of normal tissues.” During the state-of-the-art lecture “Pathophysiology and the role of the host in urosepsis”, Dr. Zafer Tandoğdu (GB) stated that sepsis is no longer considered as SIRS (systemic inflammatory response syndrome). “Sepsis is a dysregulated host response with both pro- and anti-inflammatory processes. It is important that we understand timely recognition before the transition to sepsis, and early warning scores can help detect that. We should be mindful that if there is an infection, there can be sepsis,” said Dr. Tandoğdu. Day 4: UroEvidenceHub Prof. James N’Dow (GB) presented details on the EAU’s Data Initiatives, with an overview of current and upcoming efforts by the EAU to host, manage and process real-world clinical data to fill evidence gaps in current urological knowledge. In the setting up of the new UroEvidenceHub, the first pilot of which will deal with PCa, the EAU hopes to use real-world evidence to better individualise patient care. The new “data haven” project will build on established experience and (non-urological) expertise the EAU has with the PIONEER network and OPTIMA partnership. Part of this session also addressed the highly- topical subject of Artificial Intelligence (AI) and how it might transform urology in the coming years. Dr. Michael Bussmann (DE) and Prof. Philippe Lambin (NL) explained the basic principles for successful use of AI and its expected applications within urology. The most likely tasks to be taken over by AI include image analysis, diagnosis, treatment planning, patient monitoring, administrative tasks, research and even aiding in a “hands-on” way on improving surgeons’ accuracy when operating robotically. Urinary stones In his lecture on new laser technologies, Prof. Olivier Traxer (FR) had three important take home messages. He shared the formula Energy x Frequency = Power, or J x Hz = Watts, emphasising
The prevalence of male sexual dysfunction increases with age, with over 50% of men aged 40 to 70 years reporting some degree of ED. Prevalence has also become increasingly common in young men as well, with 14.1% of males aged 18-31 reporting a diagnosis of ED and growing trends show reliance on PDE5i for erectile function in younger men.” Best of EAU23 sessions New to the scientific programme this year was the Special Session “Best of EAU23 Abstracts: An expert discussion” which showcased top-tier research on oncological and non-oncological topics, including three prize winning abstracts. Under the oncology category, the top-prize winning abstract A1163: Proteomic profiling of muscle- invasive bladder cancer treated with neoadjuvant chemotherapy described four pre-NAC and two post-NAC proteomic clusters with distinct biology and survival outcomes, alongside novel prognostic biomarkers.
The second prize was given to A0890: The Stockholm3 prostate cancer screening trial
(STHLM3): An interim analysis of mortality results after 6.5 years of follow-up which concluded that the results cautiously suggest a potential effect on reducing PCa mortality by a single intensive screening intervention using PSA and Stockholm3 in combination to the cost of increasing PCa incidence. Longer-term follow-up is needed and is underway.
EAU23 report: Year-on-year progress. . . . . 1 Overview of prizes and awards. . . . . . 4-7 EAU23 Patient Day shifts the focus to shared decision-making. . . . . . . . . . . . . 8 Clinical challenge . . . . . . . . . . . . 9 Key articles from international medical journals................ 10-11 ESUO: Testis cancer therapy and fertility. . . 13 USANZ Trainee Week 2022 impressions. . . 14 Leading journals welcome new Editors-in-Chief. . . . . . . . . . . . . 15 ESU section: ESU Urology Boot Camp Lisbon 2022. . . . 17 1st Urology Boot Camp Poland. . . . . . . 17 Joining urology’s young, promising urologists atUROBESTT.............. 19 The Greek Patient Office . . . . . . . . . 20 A 12-month update on the PRIME Trial . . . 21 ESGURS: Reconstructive options in penile cancersurgery.. . . . . . . . . . . . 23 ESFFU: Patients with bladder pain syndrome/ interstitial cystitis. . . . . . . . . . . . 24 Multiple successes for urological rare diseasenetwork. . . . . . . . . . . . 25 ESIU: New DEEP-URO study builds on GPIU success. . . . . . . . . . . . . . . 26-27 EAU RF: Introducing the JUPITER project. . 28 Prophylactic radical prostatectomy in BRCA2carriers?. . . . . . . . . . . . 29 PRAISE-U launches encouraging early detectionofPCa. . . . . . . . . . . . 29 YUO section: Updates from ESRU and YUORDay23. . . . 30 Self-injection for penile enlargement. . . . 31 Setting a new course for ESUI: Amanifesto............... 31 What have urologists and the EAU achieved in 50 years?. . . . . . . . . . 33 EAUN section: The best of EAUN23: A recap and key takeaways. . . . . . . . . . . . . . . 36 Educational Framework for Urological Nursing................ 37 The EAUN is listening to you!. . . . . . . 38 Virtual support and the ADT programme. . 39 EAUN23: Travel grant reports . . . . . . . 39 My EAUN fellowship at UV Leuven. . . . . 40 New EAUN Board Member: Marcin Popiński ............. 40
Prof. Andrea Alimonti (CH) gives the state-of-the-art lecture 'Microbiome has a role in the development of genitourinary cancers'
Dr. Manuela Tutolo (IT) presents the non-oncology First prize-winning abstract 'Similar artefact susceptibility for water- and air-filled urodynamic systems' (A0693 ) Abstract A0693: Similar artefact susceptibility for water- and air-filled urodynamic systems: Results from a randomised controlled non-inferiority trial received the top prize of the non-oncology category. The research results demonstrated that AFS are non-inferior to WFS regarding overall quality of urodynamic traces. However, both measurement systems have particular pitfalls that need to be known for problem solving during urodynamic investigation (UDI) and require awareness for accurate interpretation of UDI. The congress concluded with the Special Session “Best of EAU23: Take-home messages”, whereby a panel of experts shared the congress highlights on 10 topics, from liquid biopsy to early detection of PCa, paediatrics, BCa, functional urology, stones, benign prostatic hyperplasia, andrology, and imaging. Access more EAU23 content All webcasts, videos, posters and full-text abstracts are currently accessible via the EAU23 Resource Centre. Delegates have full access. If you did not attend EAU23, you can still register for on-demand access to explore all scientific content shared during the congress. Please note that accreditation is no longer valid. For more details, see www.eau23.org/rc
European Urology Today
Editor-in-Chief Prof. J.O.R. Sønksen, Herlev (DK)
Section Editors Prof. T.E. Bjerklund Johansen, Oslo (NO) Dr. B.C. Bujoreanu, Cluj Napoca (RO) Prof. O. Hakenberg, Rostock (DE) Dr. P. Østergren, Copenhagen (DK) Dr. G. Ploussard, Toulouse (FR) Prof. J. Rassweiler, Heilbronn (DE) Prof. O. Reich, Munich (DE) Prof. F. Sanguedolce, Barcelona (ES) Prof. S. Tekgül, Ankara (TR)
the importance of energy and power, over frequency. Secondly, when evaluating the
effectiveness of new laser technology, the real-life application should be leading as laboratory settings cannot always be reproduced bedside. Finally, Prof. Traxer presented a useful rule of thumb for the audience: for kidney stones, work from surface to centre and always use 20-25W or less. For ureteral stones, from centre to surface and using a lower frequency range of 12-15W. Plenary Session: Men’s Health Ass. Prof. Faysal Yafi (US) presented his lecture on “Wearables for erectile quality: Catchy gadget or valuable clinical instrument?”, with a summary of what is currently the market and what is planned for the market in the near future. “Wearable (electronic) devices/gadgets are gaining popularity amongst consumers and investigators for sexual function tracking, erectile dysfunction (ED) and premature ejaculation (PE).
Special Guest Editor Mr. J. Catto, Sheffield (GB)
Founding Editor Prof. F. Debruyne, Nijmegen (NL)
Editorial Team E. De Groot-Rivera, Arnhem (NL)
S. Fitts, Arnhem (NL) L. Keizer, Arnhem (NL) H. Lurvink, Arnhem (NL) EUT Editorial Office PO Box 30016 6803 AA Arnhem The Netherlands T +31 (0)26 389 0680 EUT@uroweb.org
Disclaimer No part of European Urology Today (EUT) may be reproduced without written permission from the Communication Office of the European Association of Urology (EAU). The comments of the reviewers are their own and not necessarily endorsed by the EAU or the Editorial Board. The EAU does not accept liability for the consequences of inaccurate statements or data. Despite of utmost care the EAU and their Communication Office cannot accept responsibility for errors or omissions.
Day 2: A full day of live surgery!
European Urology Today
April/May 2023
3
Powered by FlippingBook